Annotation Detail

Information
Associated Genes
FGFR3
Associated Variants
FGFR3 FGFR3-TACC3
Associated Disease
transitional cell carcinoma
Source Database
CIViC Evidence
Description
In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or more prior antineoplastic therapies. An overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization. No clear differences between type of FGFR3 aberration and response could be seen. The authors conclude that BGJ398 appears to have moderate anticancer activity in patients with metastatic urothelial carcinoma, that response rates and disease control rate exceed outcomes with most agents in this setting, and that enriching for patients with activating FGFR3 mutations together with the high specificity of BGJ398 for FGFR3 likely explains this improved response.
Variant Origin
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/6409
Gene URL
https://civic.genome.wustl.edu/links/genes/23
Variant URL
https://civic.genome.wustl.edu/links/variants/830
Rating
3
Evidence Type
Predictive
Disease
Urothelial Carcinoma
Evidence Direction
Supports
Drug
Infigratinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
29848605
Drugs
Drug NameSensitivitySupported
InfigratinibSensitivitytrue